Diabetic Foot Ulcer Mixed
3
0
1
0
Key Insights
Highlights
Treatment Research
4 treatments under study, led by Ilp100topical Emilimogene Sigulactibac 1x109 Cfucm2
Research Leaders
6 sponsors active, led by Acesso Biologics
Related Conditions
Often studied with 17 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
33.3%
1 terminated out of 3 trials
0.0%
-86.6% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (3)
Clinical Registry Collecting Real World Evidence on Wound Care Treatments
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
A Pilot Study to Assess the Efficacy of NEOX® CORD 1K® in the Treatment of Complex Diabetic Wounds
Research Network
Common Treatments
- Ilp100topical Emilimogene Sigulactibac 1x109 Cfucm21
- Various Types Of Wound Care Treatments1
- Ilp100topical Emilimogene Sigulactibac 5x107 Cfucm21
- Neox Cord 1k1
Active Sponsors
- Acesso Biologics1
- European Commission1
- Ilya Pharma1
- Siddhey LLC1
- New Horizon Medical Solutions1
Top Investigators
Johns Hopkins University
Department of Endocrinology, Skåne University Hospital, Malmö, Sweden
Related Conditions
- Diabetic Foot Ulcer2
- Diabetic Foot1
- Trauma Injury1
- Injury And Wounds1
- Vascular Ulcer Arterial Or Venous Including Diabetic Ulcers Not Located On The Foot1